Biotechnology and Life Sciences

  • Advised Black Dog Hollow on the use of biosolids to reclaim coal waste
  • Counseled drinking water utility client on the impacts of Cryptosporidium in source water
  • Assisted distillery client in enforcement action arising from ethanol spill and related hypoxia-induced fish kill
  • Served as IP counsel for the Defendant in the case of Institut Pasteur v. Simon in the Eastern District of Pennsylvania.  The case involved patents in the field of molecular combing, a technology useful in sequencing and analyzing DNA and the human genome. 

Stites attorneys have also drafted and prosecuted numerous patents in the biotechnological arts including the following:

  • U.S. Patent No. 7,850,974, entitled "Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby" was drafted by Bill Schulman and was prosecuted by Bill Schulman, Terry Wright and Mandy Wilson Decker.
  • U.S. Patent No. 7,858,388, entitled "MS based peptide and protein sequencing via reactions of lysine residues with peroxycarbonate compounds" was drafted and prosecuted by Richard Myers.
  • U.S. Patent No. 7,329,542, entitled “Probes for Identifying Cancer-Specific Antigens” was prosecuted by Bill Schulman and Stephen Weyer. This patent relates to a method for producing an antibody-secreting cell probe (ASC-probe) against a cancer-specific antigen.
  • U.S. Patent No. 7,196,220, entitled “Bone Targeting Compounds for Delivering Agents to the Bone for Interaction Therewith,” relating to the targeted delivery of agents to bone to affect treatments, such as treatment for osteoporosis or bone cancer. This patent was drafted and prosecuted by Mandy Wilson Decker.
  • U.S. Patent No. 7,253,147, entitled "Modified Serum Albumin with Reduced Affinity for Nickel and Copper,” relating to the modified structure of human serum albumin at certain of its binding regions. This patent was drafted and prosecuted by Bill Schulman.

Other recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include:

  • U.S. Patent No. 7,892,754 — Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof
  • U.S. Patent No. 7,892,542 — Human anti-idiotypic antibody fragments that mimic HER-2/neu
  • U.S. Patent No. 7,838,012 — S. aureus fibrinogen binding protein gene
  • U.S. Patent No. 7,745,589 – “Antibodies and unnatural substrates of prenylation enzymes for use in detecting and isolating prenylated proteins”
  • U.S. Patent No.  7,704,513 – “Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus”
  • U.S. Patent No. 7,691,872 – “Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds”
  • U.S. Patent No. 7,662,607 – “Chalaropsis lysozyme protein and its method of use in anti-bacterial applications”
  • U.S. Patent No. 7,615,616 – “Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby”
  • U.S. Patent No. 7,569,565 – “Pharmaceutical composition for the prevention or treatment of cerebral oedemas”
  • U.S. Patent No. 7,384,752 – “DNA Encoding a Human Imidazolie Receptor and Ligand Binding Assay Employing Same”
  • U.S. Patent No. 7,381,793 – “Extracellular Matrix-Binding Proteins from Staphylococcus Aureus”
  • U.S. Patent No. 7,375,132 – “Compounds and Methods for Inhibiting Cellular Responses to Hypoxia”
  • U.S. Patent No. 7,364,738 – “Monoclonal Antibodies to the CLFA Protein and Method of use in Treating Infections”
  • U.S. Patent No. 7,329,499 – “Use of a Novel Human ULIP6/CRMP Protein in Diagnosis of Paraneoplastic Neurological Syndromes”
  • U.S. Patent No. 7,300,651 – “Methods of Delaying Development of CEA-Associated Tumors using Anti-Idiotype Antibody 3H1”
  • U.S. Patent No. 7,229,780 – “Monoclonal Antibody Against Ovarian Carcinoma”